199 related articles for article (PubMed ID: 18329693)
1. Membrane-type-1 matrix metalloproteinase, matrix metalloproteinase 2, and tissue inhibitor of matrix proteinase 2 in prostate cancer: identification of patients with poor prognosis by immunohistochemistry.
Trudel D; Fradet Y; Meyer F; Harel F; Têtu B
Hum Pathol; 2008 May; 39(5):731-9. PubMed ID: 18329693
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression in prostate cancer.
Ross JS; Kaur P; Sheehan CE; Fisher HA; Kaufman RA; Kallakury BV
Mod Pathol; 2003 Mar; 16(3):198-205. PubMed ID: 12640098
[TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinase 9 is associated with Gleason score in prostate cancer but not with prognosis.
Trudel D; Fradet Y; Meyer F; Têtu B
Hum Pathol; 2010 Dec; 41(12):1694-701. PubMed ID: 20825973
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of the immunoexpression of matrix metalloproteinase MMP2 and its inhibitor TIMP2 in laryngeal cancer.
Danilewicz M; Sikorska B; Wagrowska-Danilewicz M
Med Sci Monit; 2003 Mar; 9(3):MT42-7. PubMed ID: 12640351
[TBL] [Abstract][Full Text] [Related]
5. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma.
Kallakury BV; Karikehalli S; Haholu A; Sheehan CE; Azumi N; Ross JS
Clin Cancer Res; 2001 Oct; 7(10):3113-9. PubMed ID: 11595703
[TBL] [Abstract][Full Text] [Related]
6. Significance of MMP-2 expression in prostate cancer: an immunohistochemical study.
Trudel D; Fradet Y; Meyer F; Harel F; Têtu B
Cancer Res; 2003 Dec; 63(23):8511-5. PubMed ID: 14679018
[TBL] [Abstract][Full Text] [Related]
7. Expression of MMP2, MMP9, MT1-MMP, TIMP1, and TIMP2 mRNA in valvular lesions of the heart.
Soini Y; Satta J; Määttä M; Autio-Harmainen H
J Pathol; 2001 Jun; 194(2):225-31. PubMed ID: 11400152
[TBL] [Abstract][Full Text] [Related]
8. In situ gene expression and localization of metalloproteinases MMP1, MMP2, MMP3, MMP9, and their inhibitors TIMP1 and TIMP2 in human renal cell carcinoma.
Bhuvarahamurthy V; Kristiansen GO; Johannsen M; Loening SA; Schnorr D; Jung K; Staack A
Oncol Rep; 2006 May; 15(5):1379-84. PubMed ID: 16596214
[TBL] [Abstract][Full Text] [Related]
9. Expression and prognostic role of MMP2, MMP9, MMP13, and MMP14 matrix metalloproteinases in sinonasal and oral malignant melanomas.
Kondratiev S; Gnepp DR; Yakirevich E; Sabo E; Annino DJ; Rebeiz E; Laver NV
Hum Pathol; 2008 Mar; 39(3):337-43. PubMed ID: 18045645
[TBL] [Abstract][Full Text] [Related]
10. Increased extracellular matrix remodeling is associated with tumor progression in human hepatocellular carcinomas.
Théret N; Musso O; Turlin B; Lotrian D; Bioulac-Sage P; Campion JP; Boudjéma K; Clément B
Hepatology; 2001 Jul; 34(1):82-8. PubMed ID: 11431737
[TBL] [Abstract][Full Text] [Related]
11. Increased expression of membrane-type matrix metalloproteinase-1 is correlated with poor prognosis in patients with osteosarcoma.
Uchibori M; Nishida Y; Nagasaka T; Yamada Y; Nakanishi K; Ishiguro N
Int J Oncol; 2006 Jan; 28(1):33-42. PubMed ID: 16327977
[TBL] [Abstract][Full Text] [Related]
12. [Prognostic value of stromal immunolabelling by MMP-2, MT1-MMP and TIMP-2 in clinically localized prostate cancer].
Semaan M; Jovenin N; Birembaut P; Menard J; Staerman F
Prog Urol; 2005 Apr; 15(2):250-4. PubMed ID: 15999602
[TBL] [Abstract][Full Text] [Related]
13. Gelatinase B expression as a prognostic factor in patients with stage II/III rectal carcinoma treated by postoperative adjuvant therapy.
Unsal D; Akyurek N; Uner A; Erpolat OP; Han U; Akmansu M; Mentes BB; Dursun A
Am J Clin Oncol; 2008 Feb; 31(1):55-63. PubMed ID: 18376229
[TBL] [Abstract][Full Text] [Related]
14. Atypical localization of membrane type 1-matrix metalloproteinase in the nucleus is associated with aggressive features of hepatocellular carcinoma.
Ip YC; Cheung ST; Fan ST
Mol Carcinog; 2007 Mar; 46(3):225-30. PubMed ID: 17219425
[TBL] [Abstract][Full Text] [Related]
15. Bovine endometrial metallopeptidases MMP14 and MMP2 and the metallopeptidase inhibitor TIMP2 participate in maternal preparation of pregnancy.
Ulbrich SE; Meyer SU; Zitta K; Hiendleder S; Sinowatz F; Bauersachs S; Büttner M; Fröhlich T; Arnold GJ; Reichenbach HD; Wolf E; Meyer HH
Mol Cell Endocrinol; 2011 Jan; 332(1-2):48-57. PubMed ID: 20887771
[TBL] [Abstract][Full Text] [Related]
16. Association of promoter polymorphisms in MMP2 and TIMP2 with prostate cancer susceptibility in North India.
Srivastava P; Lone TA; Kapoor R; Mittal RD
Arch Med Res; 2012 Feb; 43(2):117-24. PubMed ID: 22374248
[TBL] [Abstract][Full Text] [Related]
17. Expression of E-cadherin, beta-catenin, cathepsin D, gelatinases and their inhibitors in invasive ductal breast carcinomas.
Zhang YG; DU J; Tian XX; Zhong YF; Fang WG
Chin Med J (Engl); 2007 Sep; 120(18):1597-605. PubMed ID: 17908479
[TBL] [Abstract][Full Text] [Related]
18. Substantial reduction in risk of breast cancer associated with genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes.
Zhou Y; Yu C; Miao X; Tan W; Liang G; Xiong P; Sun T; Lin D
Carcinogenesis; 2004 Mar; 25(3):399-404. PubMed ID: 14604886
[TBL] [Abstract][Full Text] [Related]
19. EphA2 overexpression is associated with angiogenesis in ovarian cancer.
Lin YG; Han LY; Kamat AA; Merritt WM; Landen CN; Deavers MT; Fletcher MS; Urbauer DL; Kinch MS; Sood AK
Cancer; 2007 Jan; 109(2):332-40. PubMed ID: 17154180
[TBL] [Abstract][Full Text] [Related]
20. CD147, MMP-1, MMP-2 and MMP-9 protein expression as significant prognostic factors in human prostate cancer.
Zhong WD; Han ZD; He HC; Bi XC; Dai QS; Zhu G; Ye YK; Liang YX; Qin WJ; Zhang Z; Zeng GH; Chen ZN
Oncology; 2008; 75(3-4):230-6. PubMed ID: 18852494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
